Skip to main content

    Main navigation

    • Investors
    • About
    • News
    • Contact us
    • Egoo.health
    • en
    • sv
Home

Main navigation

  • Investors
  • About
  • News
  • Contact us
  • Egoo.health
  • en
  • sv
 

Investors

+

Main navigation

Main navigation

  • News - Press releases
  • Financial Calendar
  • Financial reports
    • IPO and listning documents
  • Corporate governance
    • Articles Of Association
    • AGM and Extraordinary general meetings
      • Extraordinary Shareholders Meeting 19 November
      • Extraordinary general meeting January 2020
      • Annual General Meeting, May 20, 2020
    • Auditor
    • Election committee
    • Certified adviser
  • Share information
    • Major shareholders
    • Sharecapital
    • Incentive programme
    • Dividend Policy
    • Warrants (TO)
  • Board
  • Management
  • Insiders
  • IR Contact
  • Presentations

Financial reports

See Financial Calendar for information on upcoming financial reports.

Annual Reports are available in Swedish only (Danish for Qlife Aps)

Qlife Interim report Q4 - 2020

Qlife Interim report Q3 - 2020

Qlife Interim report Q2 - 2020

Qlife Interim report Q1 - 2020

Qlife Holding AB Årsredovisning 2019.pdf

Qlife ApS Årsrapport 2018-19 SV.pdf

Qlife Aps Årsrapport 2018-19 DK.pdf

Qlife

Qlife Holding AB
Hamntorget 3
SE-252 21 Helsingborg, Sweden
info@egoo.health

Links

  • About
  • Investors
  • Egoo.health

Qlife’s vision is to facilitate regular blood biomarker testing from home environment. We aim to make blood sampling convenient, cheap, fast, accessible and accurate resulting in more frequent blood testing to gain insight into personal health, with increased possibility for earlier discovery of illnesses. Our product is an integrated platform consisting of a small home device, disposable capsules each a test for a specific biomarker, and a digital infrastructure that shares data with patient journal or hospital platform.